Keyword: Vaxart

Vaxart touted phase 2 data for its oral flu vaccine candidate in a trial against Sanofi's market-leading Fluzone.

Here is some other vaccine news of note for the week.

Aviragen and Vaxart merged into one company aimed at developing oral vaccines against flu, norovirus and RSV.

Vaxart has been keeping busy with R&D for its oral vaccines, and now, the company is adding another project to its list. The South San Francisco-based biotech is launching a Phase I clinical trial of its oral vaccine for norovirus.

Widening the field further, Vaxart and Immunovaccine are joining a slew of biotechs and pharmas either exploring or embarking on Zika vaccine development.